Skip to main content
. 2005 Jan 7;102(3):820–825. doi: 10.1073/pnas.0408774102

Fig. 3.

Fig. 3.

EBNA1-transgenic protein expression. (A) EBNA1 protein levels in third-generation lineages 58, 68, and 73 B220 (+) and (-) splenocytes, CD8(+) thymic cells, and total bone marrow cells were compared with levels in equal numbers of EBV-transformed human B lymphocytes, LCLs, or EBV-negative BJAB lymphoblasts (BJ). FV, FVB control cells. The protein loaded in each lane is indicated. Western blots of the same extracts with EBNA1 and tubulin antibody are shown. (B) Western blots of 40-μg protein extracts from BJ cells, BJ cells that had been converted 2-3× EBNA1 overexpression, BJFE1, or from spleens of 12th-generation lineage 73 and littermate control mice. (C) Western blot of protein extracts from kidney (Ki), liver (Li), stomach (St), brain (Br), thymus (Th), and spleen (Sp) of lineage 58 or littermate control with EBNA1-specific antibody. ns, nonspecific reactivity with hepatocyte extracts. (D) In vitro gel shift with nuclear extracts from BJFE1 cells or total cell extract from lineages 73 and 68 or littermate control splenocytes. Extracts were incubated with labeled EBNA1-cognate DNA probe in the presence or absence of EBNA1 (E1) or control (C) antibody, or wild-type (W) or mutant (M) competitor DNA.